Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores

PURPOSE: PR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed. METHODS: In this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Taobo, Chen, Yan, Liu, Yiqiang, Zhang, Danhua, Pan, Jiankang, Long, Mengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141178/
https://www.ncbi.nlm.nih.gov/pubmed/34022815
http://dx.doi.org/10.1186/s12874-021-01297-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141178/
https://www.ncbi.nlm.nih.gov/pubmed/34022815
http://dx.doi.org/10.1186/s12874-021-01297-8

Ejemplares similares